This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this articlebyintroducing citations to additional sources.
Find sources: "IDNNA" – news · newspapers · books · scholar · JSTOR (October 2019) |
![]() | |
Names | |
---|---|
Preferred IUPAC name
1-(4-Iodo-2,5-dimethoxyphenyl)-N,N-dimethylpropan-2-amine | |
Other names
2,5-Dimethoxy-4-iodo-N,N-dimethylamphetamine | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C13H20NO2I | |
Molar mass | 349.211 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
IDNNA (2,5-dimethoxy-4-iodo-N,N-dimethylamphetamine) is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N,N-dimethyl analogofDOI. IDNNA was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 2.6 mg, and the duration unknown.[1] IDNNA produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of IDNNA.
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]
![]() | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |